Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy

Robert C. Kaplan, W. H. Frishman

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Inflammation-related processes play a key role the current etiologic model of atherosclerosis and its acute complications. Recent evidence suggests that blood-based biomarkers that reflect systemic inflammation may contribute to our ability to predict future risk of cardiovascular disease. Global markers of inflammation, such as C-reactive protein and fibrinogen, have been well studied as potential cardiovascular risk factors. A variety of additional markers that reflect various elements of the complex systems governing inflammation, including proinflammatory and antiinflammatory cytokines, mediators of cellular adhesion, and matrix degradation enzymes, are also worthy of study. Although many previous studies have examined the relation of inflammation to myocardial infarction, emerging evidence suggests that other cardiovascular phenotypes such as ischemic stroke and early-stage atherosclerosis may also be related to inflammation. Further elucidating the role of inflammation in cardiovascular disease may lead to the identification of new targets for preventive or therapeutic interventions. In addition, markers of inflammation may be useful as a means to predict or monitor an individual's response to currently available cardiovascular therapies, such as aspirin or HMG coenzyme A reductase inhibitors, that may act via antiinflammatory mechanisms.

Original languageEnglish (US)
Pages (from-to)326-332
Number of pages7
JournalHeart Disease
Volume3
Issue number5
StatePublished - 2001

Fingerprint

Cardiovascular Diseases
Inflammation
Drug Therapy
Atherosclerosis
Anti-Inflammatory Agents
Coenzyme A
C-Reactive Protein
Fibrinogen
Aspirin
Oxidoreductases
Biomarkers
Stroke
Myocardial Infarction
Cytokines
Phenotype
Enzymes
Therapeutics

Keywords

  • C-reactive protein
  • Cardiovascular disease
  • Epidemiology
  • Inflammation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. / Kaplan, Robert C.; Frishman, W. H.

In: Heart Disease, Vol. 3, No. 5, 2001, p. 326-332.

Research output: Contribution to journalArticle

@article{dde6be9814014583baca85d412eefb31,
title = "Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy",
abstract = "Inflammation-related processes play a key role the current etiologic model of atherosclerosis and its acute complications. Recent evidence suggests that blood-based biomarkers that reflect systemic inflammation may contribute to our ability to predict future risk of cardiovascular disease. Global markers of inflammation, such as C-reactive protein and fibrinogen, have been well studied as potential cardiovascular risk factors. A variety of additional markers that reflect various elements of the complex systems governing inflammation, including proinflammatory and antiinflammatory cytokines, mediators of cellular adhesion, and matrix degradation enzymes, are also worthy of study. Although many previous studies have examined the relation of inflammation to myocardial infarction, emerging evidence suggests that other cardiovascular phenotypes such as ischemic stroke and early-stage atherosclerosis may also be related to inflammation. Further elucidating the role of inflammation in cardiovascular disease may lead to the identification of new targets for preventive or therapeutic interventions. In addition, markers of inflammation may be useful as a means to predict or monitor an individual's response to currently available cardiovascular therapies, such as aspirin or HMG coenzyme A reductase inhibitors, that may act via antiinflammatory mechanisms.",
keywords = "C-reactive protein, Cardiovascular disease, Epidemiology, Inflammation",
author = "Kaplan, {Robert C.} and Frishman, {W. H.}",
year = "2001",
language = "English (US)",
volume = "3",
pages = "326--332",
journal = "Heart Disease",
issn = "1521-737X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy

AU - Kaplan, Robert C.

AU - Frishman, W. H.

PY - 2001

Y1 - 2001

N2 - Inflammation-related processes play a key role the current etiologic model of atherosclerosis and its acute complications. Recent evidence suggests that blood-based biomarkers that reflect systemic inflammation may contribute to our ability to predict future risk of cardiovascular disease. Global markers of inflammation, such as C-reactive protein and fibrinogen, have been well studied as potential cardiovascular risk factors. A variety of additional markers that reflect various elements of the complex systems governing inflammation, including proinflammatory and antiinflammatory cytokines, mediators of cellular adhesion, and matrix degradation enzymes, are also worthy of study. Although many previous studies have examined the relation of inflammation to myocardial infarction, emerging evidence suggests that other cardiovascular phenotypes such as ischemic stroke and early-stage atherosclerosis may also be related to inflammation. Further elucidating the role of inflammation in cardiovascular disease may lead to the identification of new targets for preventive or therapeutic interventions. In addition, markers of inflammation may be useful as a means to predict or monitor an individual's response to currently available cardiovascular therapies, such as aspirin or HMG coenzyme A reductase inhibitors, that may act via antiinflammatory mechanisms.

AB - Inflammation-related processes play a key role the current etiologic model of atherosclerosis and its acute complications. Recent evidence suggests that blood-based biomarkers that reflect systemic inflammation may contribute to our ability to predict future risk of cardiovascular disease. Global markers of inflammation, such as C-reactive protein and fibrinogen, have been well studied as potential cardiovascular risk factors. A variety of additional markers that reflect various elements of the complex systems governing inflammation, including proinflammatory and antiinflammatory cytokines, mediators of cellular adhesion, and matrix degradation enzymes, are also worthy of study. Although many previous studies have examined the relation of inflammation to myocardial infarction, emerging evidence suggests that other cardiovascular phenotypes such as ischemic stroke and early-stage atherosclerosis may also be related to inflammation. Further elucidating the role of inflammation in cardiovascular disease may lead to the identification of new targets for preventive or therapeutic interventions. In addition, markers of inflammation may be useful as a means to predict or monitor an individual's response to currently available cardiovascular therapies, such as aspirin or HMG coenzyme A reductase inhibitors, that may act via antiinflammatory mechanisms.

KW - C-reactive protein

KW - Cardiovascular disease

KW - Epidemiology

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=0035213726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035213726&partnerID=8YFLogxK

M3 - Article

C2 - 11975814

AN - SCOPUS:0035213726

VL - 3

SP - 326

EP - 332

JO - Heart Disease

JF - Heart Disease

SN - 1521-737X

IS - 5

ER -